Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

31,147 trials

NCT07635186
Recruiting
A Study to Evaluate AHB-137 Injection in Treatment-naïve Participants With Chronic Hepatitis B
Phase 2 · China · 23 sites
Registry update: 29 Jul 2026
NCT07383441
Recruiting
Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer
Phase 3 · United States · 41 sites
Registry update: 11 Jun 2026
NCT07622836
Recruiting
A Prospective, Multicenter, Phase II Clinical Study of Postoperative Chemotherapy Combined With QL1706 for High-risk Triple-negative Breast Cancer.
Not applicable · China · 1 site
Registry update: 3 Jun 2026
NCT07321912
Recruiting
Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma
Phase 2 · United States · 3 sites
Registry update: 6 Oct 2026
NCT07446972
Recruiting
Impact of Bariatric Surgery on Female Sexual Function and Sex Hormones
Not applicable · Egypt · 1 site
Registry update: 10 Jun 2026
NCT07333066
Recruiting
Phase III Randomized International Open Label Clinical Trial of Treatment Intensification With Docetaxel Plus Apalutamide in Patients With Metastatic Hormone-sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment With Apalutamide: REINFORCE Trial.
Phase 3 · Germany, Spain, France, Italy, Portugal · 72 sites
Registry update: 17 Jun 2026
NCT07526987
Recruiting
Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis
Phase 3 · China · 3 sites
Registry update: 1 Jul 2026
NCT07435740
Recruiting
Parent-Mediated Telehealth Intervention for Insomnia in Young Autistic Children
Not applicable · United States · 3 sites
Registry update: 8 Oct 2026
NCT07453095
Recruiting
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
Phase 2 · Italy · 14 sites
Registry update: 25 Jun 2026
NCT07693036
Recruiting
hUC-MSC-Exosomes for T2DM - Safety & Efficacy
Phase 1/2 · China · 1 site
Registry update: 9 Jul 2026
NCT07434479
Recruiting
A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
Not applicable · United States · 2 sites
Registry update: 10 Jun 2026
2024-515900-38-00
Recruiting
LUMC-BOB1-B7-TCR.1 in relapsed and refractory B-cell malignancies
Phase 1/2 · Netherlands · 1 site
Registry update: 9 Feb 2026
NCT07724171
Recruiting
Long-term Outcomes After Percutaneous Patent Foramen Ovale Closure (Severance PFO Registry)
Not applicable · South Korea · 1 site
Registry update: 23 Jul 2026
NCT07430540
Recruiting
Optimising Colorectal Cancer Patient Pathways
Not applicable · United Kingdom · 1 site
Registry update: 28 Aug 2026
NCT07652736
Recruiting
A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)
Not applicable · Spain · 6 sites
Registry update: 15 Oct 2026
NCT07588152
Recruiting
Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension
Phase 4 · United States · 1 site
Registry update: 11 Jun 2026
NCT07455058
Recruiting
Water Vapor Ablation for Prostate Cancer: Long-Term Registry
Not applicable · United States · 4 sites
Registry update: 18 Aug 2026
NCT07200089
Recruiting
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Phase 1 · United States · 1 site
Registry update: 15 Oct 2026
NCT07562152
Recruiting
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 3 · Australia, Belgium, Czechia, Germany, Spain, France, United Kingdom, Georgia, Hungary, Italy, Poland, Romania, United States · 132 sites
Registry update: 6 Nov 2026
NCT07798401
Recruiting
Digital Intelligent Tongue-Pressure Biofeedback Resistance Training for Post-Stroke Dysphagia: A Randomized Controlled Trial
Phase 2 · China · 1 site
Registry update: 1 Sept 2026

Ordered by registry start date. Freshness and sponsorship never change the order.